RNF43
RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
Overview
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signalling pathway. Along with RSPO2 and ZNRF3, constitutes a master switch that governs limb specification.
Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.98, genetic association 0.57, somatic mutation 0.97, animal model 0.68). IntOGen calls it a driver in 21 cohorts (4 activating, 17 loss-of-function), covering Cholangiocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Lung Squamous Cell Carcinoma, Ovarian Epithelial Tumour and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 1 · What it is
RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 2 · What goes wrong in cancer
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled.
- 3 · How drugs use it
No product in this corpus aims at RNF43 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:18505 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q68DV7 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000108375 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: colorectal cancer 0.65, gastric cancer 0.63, prostate cancer 0.55, ovarian cancer 0.51, skin cancer 0.52, lung cancer 0.56 (GraphQL API, CC0)); IntOGen RNF43 (driver in 21 cohorts (Act 4, LoF 17); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signalling pathway. Along with RSPO2 and ZNRF3, constitutes a master switch that governs limb specification. Location: Cell membrane; Endoplasmic reticulum membrane; Nucleus envelope (UniProt). Locus 17q22 (HGNC).
- Pancreatic ductal adenocarcinoma: IntOGen driver in 7 cohorts (PAAD, PANCREAS)
- Colorectal cancer: Open Targets association 0.65 with colorectal cancer (MONDO_0005575); IntOGen driver in 3 cohorts (COAD, COADREAD)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.63 with gastric cancer (MONDO_0001056); IntOGen driver in 2 cohorts (STAD)
- Prostate cancer: Open Targets association 0.55 with prostate cancer (MONDO_0008315); IntOGen driver in 3 cohorts (PRAD, PROSTATE)
- Oesophageal cancer: IntOGen driver in 2 cohorts (ESCA)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 17 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RNF43" OR ABSTRACT:"RNF43" OR TITLE:"ring finger protein 43" OR ABSTRACT:"ring finger protein 43" OR TITLE:"E3 ubiquitin-protein ligase RNF43" OR ABSTRACT:"E3 ubiquitin-protein ligase RNF43" OR TITLE:"FLJ20315" OR ABSTRACT:"FLJ20315" OR TITLE:"RNF124" OR ABSTRACT:"RNF124" OR TITLE:"DKFZp781H0392" OR ABSTRACT:"DKFZp781H0392") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RNF43, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPALB2
Shares Lung cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
- TargetMYH9
Shares Lung cancer (all types), Oesophageal cancer, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetETV1
Shares Lung cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- TargetKDM6A
Shares Lung cancer (all types), Oesophageal cancer, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetBARD1
Shares Lung cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
- TargetLRP1B
Shares Lung cancer (all types), Oesophageal cancer, IntOGen, Pancreatic ductal adenocarcinoma.
- TargetPPP2R1A
Shares Lung cancer (all types), Endometrial cancer, IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetCDC73
Shares Lung cancer (all types), Endometrial cancer, IntOGen, Open Targets Platform.